wmjenkins: I wasn't necessarily directing my comment
at your post. I am familiar with your prior posts and
generally agree with most of thei content. I was just
tired of seeing all the Statin bashing on this board.
The reality is with 40m people on Statins in the US
alone, the mixed dyslipidaemia indication is the largest
market opportunity for AMRN, and hopefully with an
Anchor approval, an NCE granted within 2 weeks of the
PDUFA date based on an Anchor patent, partnerships ,
and possible BO are back on the table.With all the
mistakes JZ has made, I would he's he's learned
the error of his ways.